Core Viewpoint - Beijing Anshi Biotechnology Co., Ltd. is pursuing an IPO on the Sci-Tech Innovation Board, utilizing the fifth set of listing standards that focus on innovation attributes and market potential rather than current profitability [5][6]. Group 1: Company Overview - Anshi Biotechnology aims to commercialize its innovative cancer drug, Beruatinib, which is currently its only marketed product and a key asset for the company [9][10]. - The company has achieved significant revenue growth, with Q1 2025 revenue reaching approximately 64.04 million yuan, nearly five times the total revenue of 2023 [19]. Group 2: IPO and Fundraising - Anshi Biotechnology plans to raise 2.45 billion yuan through its IPO, with 1.95 billion yuan allocated for new drug research and 500 million yuan for working capital [7][21]. - The company has completed three rounds of fundraising totaling over 2.55 billion yuan, with significant participation from top venture capital firms [24][25][26]. Group 3: Product and Market Potential - Beruatinib has received conditional approval for multiple indications, including non-small cell lung cancer and glioma, and has been included in the national medical insurance directory, leading to a significant increase in sales [10][20]. - The market for MET-TKI drugs in China is projected to grow rapidly, from approximately 600 million yuan in 2024 to 27.2 billion yuan by 2035, providing a substantial growth opportunity for Anshi Biotechnology [20]. Group 4: Financial Performance and Risks - Despite revenue growth, Anshi Biotechnology has not yet achieved profitability, with cumulative losses reaching 782 million yuan by Q1 2025 [19]. - The company faces risks associated with high goodwill from acquisitions, which could impact financial performance if the core product does not meet market expectations [12][18].

转自：新华财经 在中国药谷的核心版图上，一座以"医工融合"为引擎的创新园区正崭露头角——中关村（大兴）生物医用材料产业园正以独特的定位和完善的服务，吸引着 众多生物医药前沿企业和人才在此汇聚，书写着医疗健康与前沿科技跨界融合的新篇章。 黄金区位 科学布局 中关村（大兴）生物医用材料产业园位于中关村大兴生物医药产业基地核心区域，是聚焦医工融合创新的专业化产业载体。园区坐落于基地高端产业园最密 集的核心地带，周边医疗器械园、华润产业园等产业载体星罗棋布，形成强大的产业集群效应。交通网络更是堪称"四通八达"：距六环路北臧村出口仅1.5 公里，北京地铁四号线生物医药基地站4公里可达，毗邻北京大兴国际机场，大广、京港澳等多条高速环绕，让"半小时进京、1小时通达津冀、4小时连接全 国"成为现实。 园区在空间建设上独具匠心，重点打造了专业孵化、科技服务、配套服务三大核心功能，满足企业在不同发展阶段的需求。10.7万平方米的总建筑面积里， 7栋建筑通过连廊巧妙相连，既保持独立功能又实现高效联动，为企业打造出"产学研用"无缝衔接的物理空间。A栋承担着医药基地政务中心和园区展示区 的重要角色，是外界了解园区的窗口；B、C、D、E ...

3月31日下午，2025中关村论坛年会重大成果专场发布活动举办，现场发布了面向世界科技前沿、面向经济主战 场、面向国家重大需求、面向人民生命健康4大类19项重大成果。 一、面向世界科技前沿（4项） 科技成果一：我国空间科学取得国际领先成果 发布单位：中国科学院国家空间科学中心 2024年，《国家空间科学中长期发展规划（2024—2050年）》正式发布。"天关"卫星探测到256亿光年外的伽马射 线暴，发现未知暂现天体。"夸父一号"获得国际首个Lyα卡林顿图。"慧眼"卫星首次测量黑洞X射线双星的自旋和 轨道倾角。"怀柔一号"发现迄今能量最高的伽马谱线。 科技成果二：基于原语表示的类脑互补视觉感知芯片"天眸芯" 发布单位：清华大学 清华大学团队借鉴人类视觉系统，提出基于原语表示的类脑互补视觉感知新范式，突破传统图像传感器 "分辨 率、帧率、精度、动态范围"相互制约、无法满足开放环境中视觉感知复杂需求的瓶颈，研制出"天眸芯"，降低 90%带宽，实现每秒10000帧、10bit、130dB的高速、高精度、高动态范围视觉感知。 科技成果三："晶格传质-界面生长"晶体制备新范式 发布单位：北京大学 区别于传统晶体制造方法， ...